ESC 365 - Reversal of the thrombin inhibitor dabigatran.

ESC Premium Access

Reversal of the thrombin inhibitor dabigatran.

Session: Reversal of NOACs' effect: when and how?

Topic: Drug therapy

Speaker: Associate Professor A. Niessner (Vienna, AT)

Event: ESC CONGRESS 2016

Congress Session

About the speaker

Associate Professor Alexander Niessner

Medical University of Vienna, Vienna (Austria)

6 presentations

0 follower

3 more presentations in this session

When should I use reversal agents for NOACs?

Speaker: Professor G. Lip (Liverpool, GB)

Reversal of FXa inhibitors.

Speaker: Associate Professor S. Wassmann (Munich, DE)

Will the availability of specific reversal agents change the use of NOACs?

Speaker: Professor F. Verheugt (Amsterdam, NL)

Access the full session

Reversal of NOACs' effect: when and how?

Speakers: Associate Professor A. Niessner, Professor G. Lip, Associate Professor S. Wassmann, Professor F. Verheugt

About the event

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

Congress

Related content

Open Access

Welcome and introduction.

21 May 2022

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

ESC Premium Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021

This platform is supported by